It is found that symptoms during chemotherapy should not be considered in isolation, and many symptom changes followed one main pattern, which is described as a general symptom burden, which was driven mainly by fatigue and was strongly associated with worse functioning and poorer overall quality of life.
Andrea Blasco, R. Pastor-Barriuso, P. Zamora-Auñón et al.· Quality of Life Research· 0 citations
Palbociclib has shown survival benefits in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. At present, however, no genetic predictors of palbociclib-related hematological toxicity have been validated for clinical use. The aim of t...
C. Arqueros, Marta Andrés, S. Servitja et al.· International Journal of Mol...· 0 citations
BRCA2 PVs were independently associated with poorer outcomes to first-line CDK4/6i plus ET in HR-positive/HER2-negative MBC compared with controls, especially relevant among patients with endocrine-sensitive disease.
M. Cruellas, A. Rodriguez-Hernandez, L. Carità et al.· ESMO Open· 0 citations
These findings warrant prospective integration of the signatures into risk-stratified clinical trials to support future de-escalation and escalation strategies, enabling a better balance of efficacy, toxicity, cost, and drug availability.
B. Huraiová, M. Gala, L. Barroso et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
